Original Research ArticleHyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer
Highlights
► We successfully prepared hyaluronic acid coated, paclitaxel loaded, nanostructured lipid carriers (HA-NLCs) via electrostatic attraction. ► The in vitro cytotoxicity of HA-NLCs was superior to that of Taxol® in B16, CT26 and HCT116 cell lines. ► The in vivo antitumor effect of HA-NLCs in B16-bearing Kunming mice was extremely promising. ► HA-NLC prepared via electrostatic attraction was an effective carrier for delivering paclitaxel PTX to tumors overexpressing CD44.
Introduction
Paclitaxel (PTX), an effective chemotherapeutic drug isolated from the bark of Taxus brevifolia, is a microtubule-stabilizing agent that can induce mitotic arrest and cell apoptosis [1], [2]. Currently, PTX is widely used for the treatment of cancer, including ovarian, breast and nonsmall-cell lung cancer [3]. However, PTX is a hydrophobic drug, which has limited its clinical application. To date, there are two formulations approved by the FDA, PTX-Cre (Taxol®) and albumin-bound PTX (nabTM-PTX; Abraxane®). Taxol® requires dissolving PTX in polyoxyethylated castor oil (Cremophor® EL) and ethanol (CrEL), which usually leads to severe adverse side effects, including hypersensitivity, neurotoxicity and nephrotoxicity [4], [5]. Therefore, premedication with corticosteroids and antihistamines is required to reduce the risk of hypersensitivity reactions when patients are treated with Taxol®. Abraxane®, a CrEL-free formulation that was approved by the FDA in 2005, reduces the risk of hypersensitivity reactions and does not require premedication. However, Abraxane® is a non-targeted drug carrier and accumulates in tumors by the enhanced permeability and retention effect (EPR) in cancer tissues [6]. The absence of selective targeting to the tumor usually results in low antitumor activity and severe side effects. Therefore, an active tumor-targeting delivery system of chemotherapeutic drugs is urgently needed.
Various targeting molecules have been applied to target PTX to tumor tissues, such as folic acid, RGD, biotin and hyaluronic acid (HA) [7], [8], [9], [10], [11]. Among these, hyaluronic acid has been widely investigated due to its unique properties. HA is a negatively charged linear polysaccharide composed of repeating units of glucuronic acid (GlcUA) and N-acetyl-D-glucosamine (GlcNAc) linked by alternating β-1,4 and β-1,3 glycosidic bonds. HA, the main component of the extracellular matrix, binds specifically to CD44, an extracellular protein on cell membranes, and regulates diverse cellular responses. CD44 is a cell surface marker that is overexpressed in tumors and has low expression in normal tissues. The specific binding of HA to CD44 and the EPR effect of macromolecules in cancers provide new options for active tumor targeting. In addition, several formulations have been developed: hyaluronic acid-drug conjugates, hyaluronic acid nanogels and hyaluronic acid-decorated nanoparticles [12]. Hyaluronic acid-conjugated nanoparticles have been extensively studied because of the following advantages: (1) most NPs can be modified with HA; (2) HA is on the outer shell of particles, which can bind specifically to CD44; (3) HA can protect NPs and regulate the circulation time and biodistribution of NPs; and (4) multifunctional NPs can be obtained with further modifications of HA or NPs. Hyaluronic acid-conjugated nanoparticles can be obtained by covalent bond modification or electrostatic attraction. Covalent bond modification requires chemical reactions, which are complex processes that are poorly reproducible. However, the process of electrostatic attraction is simple and controllable without introducing chemical reagents. Therefore, electrostatic attraction may be an alternative to covalent bond modification.
Nanostructured lipid carriers (NLC), introduced in late 1990s, are extensively applied in chemotherapeutic drug delivery because of their unique properties and advantages. NLC, developed from solid lipid nanoparticles (SLNs), are composed of solid lipid matrices and spatially incompatible liquid lipids, which results in imperfections in the crystal structure and increases drug loading [13]. The advantages of NLC are the following: biocompatibility and biodegradability; controlled drug release; high drug loading; passive and active targeting; and the possibility of large-scale production [14]. Furthermore, NLC can prolong the circulation time of PTX and increase the accumulation of drug in tumors due to the EPR effects in tumors. Therefore, NLC may be the ideal lipid-based carrier for a PTX delivery system.
In this work, we developed a new, active, tumor target delivery system: hyaluronic acid-coated nanostructured lipid carriers (HA-NLC) obtained via electrostatic attraction for targeting PTX to tumors. The schematic representation of the structure of the HA-NLC is shown in Fig. 1. The advantages of the system include the following: (1) the materials composing the HA-NLC were biocompatible and biodegradable; (2) the drug loading was high; (3) HA-NLC was an active tumor target delivery system; and (4) the HA-NLC was prepared via electrostatic attraction, which was simple and controllable without complex chemical reactions. To our knowledge, this report is the first to prepare HA-NLC via electrostatic attraction for tumor targeting. First, the cationic PTX-NLC was prepared, and the characterization was studied. Then, HA with a molecular weight of 300 kDa was selected for the preparation of HA-NLC. We investigated the in vitro cytotoxicity of HA-NLC in three CD44-overexpressing cell lines. Finally, the antitumor efficacy and tissue distribution were evaluated in B16-bearing Kunming mice.
Section snippets
Materials
Paclitaxel was provided by Chenxin Pharmaceutical Co Ltd. (China). Glyceryl monostearate was purchased from Shanghai Chineway Pharmaceutical Tech. Co Ltd. (China). Soybean oil for injection was purchased from Zhejiang Tianyushan Pharmaceutical Co Ltd. (China). Injectable soya lecithin (phosphatidylcholine accounts for 95%, pH = 5.0–7.0.) was purchased from Shanghai Taiwei Pharmaceutical Co Ltd. (China). Hexadecyl trimethyl ammonium bromide (CTAB) was purchased from Tianjin Damao Chemical Reagent
Characterization of PTX-NLC and HA-NLC
The cationic PTX-NLC was prepared by melt emulsion technology, and the optimum formulation was determined (Table 1). Lyophilization of PTX-NLC with 3% mannitol had little effect on the characterization compared with PTX-NLC before lyophilization (Table 1), and the morphology remained stable (Fig. 2). The results showed that PTX-NLC had a high EE and DL, which was suitable for PTX delivery. The zeta potential of PTX-NLC was 70.57 ± 5.17 mV, which provided a basis for HA modification (see Table 2).
Discussion
Nanoparticles modified with HA have previously been designed for the tumor-targeted delivery of PTX [23]. Generally, HA has been linked to the surface of NPs by covalent modification. However, the chemical reactions involved in the formation of HA-NPs were complicated and were not reproducible. The introduction of chemical reagents may even cause toxicity. Therefore, simple and controllable methods were the ideal choice for the surface modification of NPs, such as electrostatic attraction. HA
Acknowledgment
This work was supported by the Special Funds for Independent Innovative Natural Sciences Research of Shandong University (No. 2010JC019).
References (24)
- et al.
Paclitaxel and its formulations
Int. J. Pharm.
(2002) - et al.
Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors
Biomaterials
(2010) - et al.
Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect
J. Control Release
(2010) - et al.
Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel
J. Control Release
(2009) - et al.
Gold nanoparticles surface-functionalized with paclitaxel drug and biotin receptor as theranostic agents for cancer therapy
Biomaterials
(2012) - et al.
Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel
Colloids Surf. B. Biointerfaces
(2011) - et al.
Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells
Int. J. Pharm.
(2008) - et al.
PEGylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation
Int. J. Pharm.
(2011) - et al.
Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate
Biomaterials
(2010) - et al.
Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels
J. Control Release
(2007)
DNA/polyethyleneimine/hyaluronic acid small complex particles and tumor suppression in mice
Biomaterials
Hyperthermic enhancement of the apoptotic and antiproliferative activities of paclitaxel
Pharmacology
Cited by (219)
Double layer spherical nanoparticles with hyaluronic acid coating to enhance oral delivery of exenatide in T2DM rats
2023, European Journal of Pharmaceutics and BiopharmaceuticsTraversing the diverse avenues of exopolysaccharides-based nanocarriers in the management of cancer
2023, Carbohydrate PolymersLipid-based nanomaterials as phototheranostic agents
2023, Organic Nanomaterials for Cancer PhototheranosticsHyaluronic acid-based nanosystems for theranostic delivery and imaging
2023, Polymeric Nanosystems: Theranostic Nanosystems: Volume 1